Related Experiment Video
Updated: Aug 10, 2025
09:16
Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
Published on: June 18, 2020
6.9K
[Eosinophilic granulomatosis with polyangiitis]
Carlos Romero Gómez1, Halbert Hernández Negrín1, María Del Mar Ayala Gutiérrez1
1Internal Medicine Department, Regional University Hospital of Málaga, Biomedical Research Institute of Málaga (IBIMA), University of Málaga (UMA), Málaga, España.
Medicina Clinica
|February 11, 2023
Summary
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis often linked to asthma and eosinophilia. Recent advancements include new treatments and revised criteria for this multi-organ disease.
Area of Science:
- Rheumatology
- Immunology
- Pulmonology
Background:
- Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis.
- It is characterized by asthma, eosinophilia, and eosinophilic infiltration of various organs.
- Small and medium-sized vessel vasculitis is a key feature.
Purpose of the Study:
- To summarize recent progress in understanding EGPA pathophysiology.
- To highlight advancements in treatment, including biologic agents.
- To note revisions in classification criteria and therapeutic recommendations.
Main Methods:
- Literature review of recent studies on EGPA.
- Analysis of updated classification criteria.
- Evaluation of new therapeutic strategies and recommendations.
Main Results:
- EGPA affects multiple organs, including lungs, skin, and the peripheral nervous system.
- Anti-neutrophil cytoplasmic antibody (ANCA) is present in less than half of EGPA patients.
- Glucocorticoids and immunosuppressants have been traditional treatments.
Conclusions:
- Recent years have seen significant progress in EGPA knowledge.
- Biologic agents represent a new frontier in EGPA treatment.
- Revised classification and updated recommendations guide current management.
Related Concept Videos
01:24Nephrotic Syndrome I : Introduction
17
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
17
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
240
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
240
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
214
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
214
01:30Peptic Ulcer Disease I: Introduction
244
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
244
01:17Gastritis-II: Pathophysiology
426
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
426